OBJECTIVE: To examine the temporal and dose-related effects of glucocorticoids (GCs) on body mass index (BMI) in children with rheumatic diseases. METHODS: Children initiating GCs for a rheumatic disease (n = 130) were assessed every 3 months for 18 months. BMI, weight, and height Z score trajectories were described according to GC starting dosage in prednisone equivalents: high (≥1.0 mg/kg/day), low (<0.2 mg/kg/day to a maximum of 7.5 mg/day), and moderate (between high and low) dosage. The impact of GC dosing, underlying diagnosis, pubertal status, physical activity, and disease activity on BMI Z scores and on percent body fat was assessed with longitudinal mixed-effects growth curve models. RESULTS: The GC starting dose was high in 59% and moderate in 39% of patients. The peak BMI Z score was +1.29 at 4 months with high-dose GCs and +0.69 at 4.2 months with moderate-dose GCs (P < 0.001). Overall, 50% (95% confidence interval 41-59%) of the children returned to within +0.25 SD of their baseline BMI Z score. Oral GC dose over the preceding 3 months was the most significant determinant of BMI Z score and percent body fat. The proportion of days in receipt of GCs, disease activity, and a diagnosis of systemic-onset juvenile idiopathic arthritis were also associated with BMI Z scores. The correlation between changes in BMI and changes in percent body fat was 0.09. CONCLUSION: In children with rheumatic diseases starting moderate and high doses of GCs, BMI Z scores peaked at 4 months, and only half returned to within +0.25 SD of their baseline BMI Z score after 18 months.
OBJECTIVE: To examine the temporal and dose-related effects of glucocorticoids (GCs) on body mass index (BMI) in children with rheumatic diseases. METHODS:Children initiating GCs for a rheumatic disease (n = 130) were assessed every 3 months for 18 months. BMI, weight, and height Z score trajectories were described according to GC starting dosage in prednisone equivalents: high (≥1.0 mg/kg/day), low (<0.2 mg/kg/day to a maximum of 7.5 mg/day), and moderate (between high and low) dosage. The impact of GC dosing, underlying diagnosis, pubertal status, physical activity, and disease activity on BMI Z scores and on percent body fat was assessed with longitudinal mixed-effects growth curve models. RESULTS: The GC starting dose was high in 59% and moderate in 39% of patients. The peak BMI Z score was +1.29 at 4 months with high-dose GCs and +0.69 at 4.2 months with moderate-dose GCs (P < 0.001). Overall, 50% (95% confidence interval 41-59%) of the children returned to within +0.25 SD of their baseline BMI Z score. Oral GC dose over the preceding 3 months was the most significant determinant of BMI Z score and percent body fat. The proportion of days in receipt of GCs, disease activity, and a diagnosis of systemic-onset juvenile idiopathic arthritis were also associated with BMI Z scores. The correlation between changes in BMI and changes in percent body fat was 0.09. CONCLUSION: In children with rheumatic diseases starting moderate and high doses of GCs, BMI Z scores peaked at 4 months, and only half returned to within +0.25 SD of their baseline BMI Z score after 18 months.
Authors: Stephen R Daniels; Marc S Jacobson; Brian W McCrindle; Robert H Eckel; Brigid McHugh Sanner Journal: Circulation Date: 2009-03-30 Impact factor: 29.690
Authors: A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward Journal: Arthritis Care Res (Hoboken) Date: 2010-04 Impact factor: 4.794
Authors: Jacqueline Halton; Isabelle Gaboury; Ronald Grant; Nathalie Alos; Elizabeth A Cummings; Maryann Matzinger; Nazih Shenouda; Brian Lentle; Sharon Abish; Stephanie Atkinson; Elizabeth Cairney; David Dix; Sara Israels; David Stephure; Beverly Wilson; John Hay; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Bone Miner Res Date: 2009-07 Impact factor: 6.741
Authors: Otto T H M Lelieveld; Marco van Brussel; Tim Takken; Ellen van Weert; Miek A van Leeuwen; Wineke Armbrust Journal: Arthritis Rheum Date: 2007-08-15
Authors: René van Gent; Cornelis K van der Ent; Liesbeth E M van Essen-Zandvliet; Maroeska M Rovers; Jan L L Kimpen; Gea de Meer; Peter H C Klijn Journal: Pediatr Pulmonol Date: 2007-11
Authors: Greg D Wells; Donna L Wilkes; Jane Schneiderman-Walker; Maryam Elmi; Elizabeth Tullis; Larry C Lands; Felix Ratjen; Allan L Coates Journal: Pediatr Pulmonol Date: 2008-04
Authors: Matthew L Basiaga; Evanette K Burrows; Michelle R Denburg; Kevin E Meyers; Andrew B Grossman; Petar Mamula; Robert W Grundmeier; Jon M Burnham Journal: J Pediatr Date: 2016-09-09 Impact factor: 4.406
Authors: Ashley P Jones; Dannii Clayton; Gloria Nkhoma; Frances C Sherratt; Matthew Peak; Simon R Stones; Louise Roper; Bridget Young; Flora McErlane; Tracy Moitt; Athimalaipet V Ramanan; Helen E Foster; Paula R Williamson; Samundeeswari Deepak; Michael W Beresford; Eileen M Baildam Journal: Health Technol Assess Date: 2020-07 Impact factor: 4.014
Authors: Jaime Guzman; Tristan Kerr; Leanne M Ward; Jinhui Ma; Kiem Oen; Alan M Rosenberg; Brian M Feldman; Gilles Boire; Kristin Houghton; Paul Dancey; Rosie Scuccimarri; Alessandra Bruns; Adam M Huber; Karen Watanabe Duffy; Natalie J Shiff; Roberta A Berard; Deborah M Levy; Elizabeth Stringer; Kimberly Morishita; Nicole Johnson; David A Cabral; Maggie Larché; Ross E Petty; Ronald M Laxer; Earl Silverman; Paivi Miettunen; Anne-Laure Chetaille; Elie Haddad; Lynn Spiegel; Stuart E Turvey; Heinrike Schmeling; Bianca Lang; Janet Ellsworth; Suzanne E Ramsey; Johannes Roth; Sarah Campillo; Susanne Benseler; Gaëlle Chédeville; Rayfel Schneider; Shirley M L Tse; Roxana Bolaria; Katherine Gross; Debbie Feldman; Bonnie Cameron; Roman Jurencak; Jean Dorval; Claire LeBlanc; Claire St Cyr; Michele Gibbon; Rae S M Yeung; Ciarán M Duffy; Lori B Tucker Journal: Pediatr Rheumatol Online J Date: 2017-08-22 Impact factor: 3.054
Authors: Judith Wienke; Felicitas Bellutti Enders; Johan Lim; Jorre S Mertens; Luuk L van den Hoogen; Camiel A Wijngaarde; Joo Guan Yeo; Alain Meyer; Henny G Otten; Ruth D E Fritsch-Stork; Sylvia S M Kamphuis; Esther P A H Hoppenreijs; Wineke Armbrust; J Merlijn van den Berg; Petra C E Hissink Muller; Janneke Tekstra; Jessica E Hoogendijk; Claire T Deakin; Wilco de Jager; Joël A G van Roon; W Ludo van der Pol; Kiran Nistala; Clarissa Pilkington; Marianne de Visser; Thaschawee Arkachaisri; Timothy R D J Radstake; Anneke J van der Kooi; Stefan Nierkens; Lucy R Wedderburn; Annet van Royen-Kerkhof; Femke van Wijk Journal: Arthritis Rheumatol Date: 2019-03-12 Impact factor: 10.995
Authors: Flora McErlane; Roberto Carrasco; Lianne Kearsley-Fleet; Eileen M Baildam; Lucy R Wedderburn; Helen E Foster; Yiannis Ioannou; S E Alice Chieng; Joyce E Davidson; Wendy Thomson; Kimme L Hyrich Journal: Semin Arthritis Rheum Date: 2017-11-07 Impact factor: 5.532